

QUEST DIAGNOSTICS INC  
Form 8-K  
May 18, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 18, 2016

Quest Diagnostics Incorporated  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or other jurisdiction of Incorporation)

001-12215                                      16-1387862  
(Commission File Number)                      (I.R.S. Employer Identification No.)

Three Giralda Farms                                      07940  
Madison, NJ 07940  
(Address of principal executive offices)      (Zip Code)

(973) 520-2700  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

On May 18, 2016 Quest Diagnostics Incorporated issued a press release (the "Press Release") announcing, among other things, (i) that it completed the recently announced sale of its Focus Diagnostics products business and (ii) an updated outlook for full year 2016. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 8.01. Other Events

The Press Release also announces that Quest Diagnostics plans to use the proceeds of the sale of the Focus Diagnostics products business to repurchase its common stock, which is consistent with its strategy to deliver disciplined capital deployment and will bring the amount of capital stock repurchased since 2012 to approximately \$2 billion.

Item 9.01. Financial Statements and Exhibits

d. Exhibit Description

99.1 Press release of Quest Diagnostics Incorporated dated May 18, 2016.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

May 18, 2016

QUEST DIAGNOSTICS  
INCORPORATED

By: /s/ William J. O'Shaughnessy, Jr.  
William J. O'Shaughnessy, Jr.  
Deputy General Counsel and  
Corporate Secretary